Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Oncogene

• Publication date

  2014-02-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2013.41PMID 23474757
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies

  2014cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

  2011cited by this paper
• Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

  2011cited by this paper
• Gene expression profiling in breast cancer: classification, prognostication, and prediction.

  2011cited by this paper
• Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

  2011cited by this paper
• Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

  2011cited by this paper
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling

  2011cited by this paper
• Functional viability profiles of breast cancer.

  2011cited by this paper
• A census of amplified and overexpressed human cancer genes

  2010cited by this paper
• Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

  2010cited by this paper
• DNA amplifications in breast cancer: genotypic-phenotypic correlations.

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

  2010cited by this paper
• Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA

  2010cited by this paper
• The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

  2010cited by this paper
• Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

  2010cited by this paper
• Emerging targeted therapies for breast cancer.

  2010cited by this paper
• Her2 Activates NF-κB and Induces Invasion Through the Canonical Pathway Involving IKKα

  2009cited by this paper
• Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer

  2009cited by this paper
• Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

  2009cited by this paper
• Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

  2009cited by this paper
• The genomic profile of HER2‐amplified breast cancers: the influence of ER status

  2008cited by this paper
• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  2008cited by this paper
• Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

  2008cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007cited by this paper
• Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

  2007cited by this paper
• Emerging targeted therapies for breast cancer.

  2007cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

  2007cited by this paper
• Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

  2006cited by this paper
• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation.

  2005cited by this paper
• Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

  2005cited by this paper
• NIBP, a Novel NIK and IKKβ-binding Protein That Enhances NF-κB Activation*

  2005cited by this paper
• PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

  2005cited by this paper
• HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.

  2004cited by this paper
• HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

  2004cited by this paper
• Reprogramming RelA

  2004cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

  2002cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• TRAPP I implicated in the specificity of tethering in ER-to-Golgi transport.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

  1999cited by this paper
• NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.

  1998cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-B-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular Transformation (*)

  1996cited by this paper
• Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2

  1995cited by this paper
• Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

  1995cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer

  2025cites this paper
• TRAPPopathies: Severe Multisystem Disorders Caused by Variants in Genes of the Transport Protein Particle (TRAPP) Complexes

  2024cites this paper
• TREMSUCS-TCGA – an integrated workflow for the identification of biomarkers for treatment success

  2024cites this paper
• Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

  2022cites this paper
• Breast Cancer Treatments: Updates and New Challenges

  2021cites this paper
• How Physiologic Targets Can Be Distinguished from Drug-Binding Proteins

  2021cites this paper
• Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview.

  2021cites this paper
• HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib

  2021cites this paper
• CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.

  2021cites this paper
• miR‐221 confers lapatinib resistance by negatively regulating p27kip1 in HER2‐positive breast cancer

  2021cites this paper
• Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs.

  2020cites this paper
• Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

  2020cites this paper
• CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-TKI via suppressing PI3K/AKT

  2020cites this paper
• Experimental and computational evaluation of kolliphor RH 40 as a new fluorescence enhancer in development of a micellar-based spectrofluorimetric method for determination of lapatinib in tablets and urine

  2020cites this paper
• Lapatinib Decreases the Preimplantation Aneuploidy Rate of in vitro Fertilized Mouse Embryos without Affecting Completion of Preimplantation Development

  2020cites this paper
• The Evolving Landscape of HER2-Directed Breast Cancer Therapy

  2020cites this paper
• Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer

  2020cites this paper
• Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer

  2020cites this paper
• Targeting Rac and Cdc42 GEFs in Metastatic Cancer

  2020cites this paper
• Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

  2020cites this paper
• Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib

  2019cites this paper
• A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma

  2019cites this paper
• Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.

  2019cites this paper
• A Case-Control Study of the Relationship between LINC01495, TRAPPC9 Polymorphisms and Lung Cancer Susceptibility in Northeast Chinese Population

  2018cites this paper
• HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy

  2018cites this paper
• Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells

  2018cites this paper
• Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines

  2017cites this paper
• Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells

  2016cites this paper
• Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

  2016cites this paper
• Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer

  2016cites this paper
• A bead-based western for high-throughput cellular signal transduction analyses

  2016cites this paper
• Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis

  2016cites this paper
• A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression

  2016cites this paper
• Characterization of the binding of an anticancer drug, lapatinib to human serum albumin.

  2016cites this paper
• Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms

  2016cites this paper
• RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment

  2016cites this paper
• Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches.

  2016cites this paper
• TRAPP Complexes in Secretion and Autophagy

  2016influential citation
• Adaptive stress signaling in targeted therapy resistance in cancer

  2015cites this paper
• Use of genetically engineered mouse models in preclinical drug development

  2015cites this paper
• Mechanisms of lapatinib resistance in HER2-driven breast cancer.

  2015cites this paper
• Elevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NFκB signaling

  2015cites this paper
• Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients

  2015cites this paper
• IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma

  2015influential citation
• A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression

  2014cites this paper
• Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models

  2014cites this paper
• Finding effective cancer therapies through loss of function genetic screens.

  2014cites this paper
• In Sickness and in Health: The Role of TRAPP and Associated Proteins in Disease

  2014cites this paper
• Bayesian inference for protein signalling networks

  2013cites this paper
• RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis

  2013cites this paper